
Quisinostat 2HCl
CAS No. 875320-31-3
Quisinostat 2HCl ( —— )
产品货号. M17639 CAS No. 875320-31-3
Quisinostat (JNJ-26481585) 2HCl 是一种新型第二代 HDAC 抑制剂,对 HDAC1 具有最高效力,在无细胞测定中 IC50 为 0.11 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥1045 | 有现货 |
![]() ![]() |
10MG | ¥1839 | 有现货 |
![]() ![]() |
25MG | ¥2827 | 有现货 |
![]() ![]() |
50MG | ¥3702 | 有现货 |
![]() ![]() |
100MG | ¥5338 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Quisinostat 2HCl
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Quisinostat (JNJ-26481585) 2HCl 是一种新型第二代 HDAC 抑制剂,对 HDAC1 具有最高效力,在无细胞测定中 IC50 为 0.11 nM。
-
产品描述Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2.(In Vitro):JNJ-26481585 inhibits HDAC isozymes in vitro.JNJ-26481585 (30-1000 nM; 24 hours) is a potent pan-HDAC inhibitor in tumor cells.JNJ-26481585 has broad spectrum antiproliferative activity against solid and hematologic cancer cell lines and induces apoptosis.(In Vivo):JNJ-26481585 (40 mg/kg; p.o.; once daily, for 3 days) as a potent HDAC1 inhibitor p21waf1,cip1 ZsGreen tumors in vivo.JNJ-26481585 induces continuous H3 acetylation in tumor tissue in vivo.JNJ-26481585 (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts.
-
体外实验JNJ-26481585 inhibits HDAC isozymes in vitro.JNJ-26481585 (30-1000 nM; 24 hours) is a potent pan-HDAC inhibitor in tumor cells.JNJ-26481585 has broad spectrum antiproliferative activity against solid and hematologic cancer cell lines and induces apoptosis. Western Blot Analysis Cell Line:Human A2780 ovarian carcinoma cells Concentration:30 nM, 100 nM, 300 nM, 1000 nM Incubation Time:24 hours Result:Induced H3 and H4 acetylation at concentrations as low as 30 to 100 nM.
-
体内实验JNJ-26481585 (40 mg/kg; p.o.; once daily, for 3 days) as a potent HDAC1 inhibitor p21waf1,cip1 ZsGreen tumors in vivo.JNJ-26481585 induces continuous H3 acetylation in tumor tissue in vivo.JNJ-26481585 (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts. Animal Model:NMRI nude mice, with HCT116 colon carcinoma cells xenografts Dosage:10 mg/kg Administration: Intraperitoneal injection, once daily, for 14 days Result:Strongly inhibited the growth of large pre-established HCT116 colon xenografts.
-
同义词——
-
通路Metabolic Enzyme/Protease
-
靶点Retinoid Receptor
-
受体HDAC1| HDAC10| HDAC11| HDAC2| HDAC4
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number875320-31-3
-
分子量467.39
-
分子式C21H28Cl2N6O2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 31.25 mg/mL (66.86 mM)
-
SMILESCl.Cl.CN1C=C(CNCC2CCN(CC2)C2=NC=C(C=N2)C(=O)NO)C2=CC=CC=C12
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years